Renal Cell Carcinoma: A Complex Therapeutic Challenge in the Elderly

Mashood Iqbal 1

1. Internal Medicine, Jinnah Medical College Hospital, Karachi, PAK

Corresponding author: Mashood Iqbal, mashhood1168@gmail.com

Abstract

An increase in age and the occurrence of renal cell carcinoma have been positively correlated. A strict therapeutic protocol for early diagnosis, screening, prevention, and population awareness needs to be well-established as a rationale to approach the morbidity at a treatment-eligible phase in the aged. Genetic predisposition appears to have a minor role in the disease pathology. Imaging modalities, providing high-resolution images of the tumor, have undoubtedly benefitted the diseased subset in aiding the diagnosis, however, a preliminary guideline protocol for its early implication in concordance with the initial symptoms needs to be adopted. Burdening of the geriatric age group by concomitant co-morbidities further deteriorates the devastating effects of the primary tumor, which, in total, appear to evolve as a final, complex stage of the illness in the majority, leading to an eventual high mortality rate. Despite being a challenging task for managing the tumor, age should not be considered the sole treatment barrier for approaching the disease.

Introduction And Background

The management of renal cell cancer in the elderly has been highlighted as a complex physician task where the occurrence of morbidity has been strongly correlated to an increase in age [1-3]. Malignant tumors of the kidney account for more than 2% of cancer incidence with more than 80% of kidney cancers arising in the renal parenchyma and the remainder in the renal pelvis [3]. Renal cell carcinoma (RCC) has the highest mortality rate of genitourinary cancers, with a steady rise in its incidence claiming it to specifically involve a higher proportion of the elderly population [4-6]. New studies have also emphasized the role of obesity, a co-morbidity, in the development of the neoplasm [7]. This cancer has been primarily addressed throughout the literature as a disease of the elderly, typically presenting in the sixth and seventh decades of life [8].

Advanced age and co-morbidities have been clearly regarded as treatment barriers where the co-morbidities as a domain are bound to be more prevalent in the aged in comparison to the young, with surgical removal of the tumor being the only potentially curative therapy in early-stage RCC. The fundamental need for cost-effective screening programs with geriatric counseling sessions due to an increased ratio of co-morbidity-related peri-operative mortality has been highlighted to make a difference in the future of renal cell cancer therapeutics [2,5-6].

Review

RCC symptomatology, statistics, and demographic data

Renal cell carcinoma evolves as the ninth most common cancer worldwide, with an overall five-year survival rate residing at 75.2% along with the morbidity being clearly labeled as highly fatal [7,9]. The National Cancer Institute emphasizes an intriguing five-year survival pattern at 93% with the tumor being localized. Their statistics also reveal an estimated discovery of new cases amounting to 79,000 in 2022, securing its eighth position among the top 10 most common neoplasms encountered [10]. The global incidence rate of diagnosis occurs at 2% with an increase in its overall worldwide occurrence. Prior epidemiological data have clearly revealed an estimated relative risk of the disease at 1.7 for men in comparison to women; males diagnosed 1.7 times more likely than females. The latter gender disparity was based according to the 2018 GLOBOCAN Data where 403,000 were annually diagnosed with neoplastic lesions in the kidney [11]. Prior published data has also claimed RCC as the third most common urogenital cancer worldwide with an incidence of about 200,000 cases worldwide annually where the latter is expressed per 100,000 population [1,12].

Age, in specific, has been graded as a non-modifiable entity where 75 years and older subset have been depicted as having the largest rise in the incidence of the disease [11]. In contrast to this robust correlation of the disease with increasing age, the Canadian Journal of Urology has also recently concluded that renal...
Despite the rarity of renal cell tumors in adolescents, the preferred treatment of mainstay overall appears to hemodialysis toward the development of ultimate RCC burden of the intervention to acquire the malignancy at a higher pace and conclude a steady relationship of control group with a significant difference of 1.6% to 0.8%, respectively, emphasizing the pathological comparative survey revealed the incidence of genitourinary cancer in patients who underwent HD versus the been clearly linked with an increased risk of progression toward RCC. Similarly, the overall relative risk of considering that hemodialysis (HD), a widely used form of renal replacement therapy in the elderly, has highlights the effect co-morbidities can have alongside cancer, hence further burdening the frail subset. Studies suggest that 30% of patients with RCC die because of conditions other than the latter. This highlights the effect co-morbidities can have alongside cancer, hence further burdening the frail subset. Considering that hemodialysis (HD), a widely used form of renal replacement therapy in the elderly, has been clearly linked with an increased risk of progression toward RCC. Similarly, the overall relative risk of RCC is 5-10-times higher in patients with end-stage renal failure. In accordance with the use of HD, a comparative survey revealed the incidence of genitourinary cancer in patients who underwent HD versus the control group with a significant difference of 1.6% to 0.8%, respectively, emphasizing the pathological burden of the intervention to acquire the malignancy at a higher pace and conclude a steady relationship of hemodialysis toward the development of ultimate RCC.

Despite the rarity of renal cell tumors in adolescents, the preferred treatment of mainstay overall appears to
particularly to be thoroughly considered in the elderly as for immediate intervention. This can be mentioned as the least invasive yet effective therapeutic strategy could be reassured that if progression occurs, a delayed operation can be proposed, with the same outcome observed slow growth rate of small renal masses. This monitoring can be highly successful where patients Active surveillance evolves as an important observational tool, particularly in those patients with an intriguing results enlighten a distinct physician approach that may be eventually considered as a rationale for the elderly subset.

Primary tumor evaluation in developing countries, such as Pakistan, involves ultrasound where the literature suggests that if the modality is executed on every patient presenting with specific and nonspecific symptoms in the urology outpatient department, RCCs can easily be diagnosed in the early stages for better survival outcomes. Hence, this provokes the need for regular physician follow-ups for a preliminary and efficacious confirmatory detection of RCC. The disease has also been regarded as a financial burden on the health care setup, hence, this is an alarm to effectively acknowledge and deliver morbidity management effectively.

RCC treatment strategy

Surgical Intervention

When considering the treatment of the lethal morbidity, a study has strongly pointed out that the disease, if advanced, is highly resistant to systemic therapy. Despite the resistance, the first interventionist physician approach strategy that has been highlighted is the standard curative approach for localized RCC involving surgical excision with total nephrectomy. The positive role of this procedure for the elderly subset remains unclear; however, for the frail subset, a high risk of complications awaits their post-interventional phase. The concept of an ideal balance between the risk and benefit of surgery needs to be addressed cautiously, again creating a complex therapeutic challenge for the physician.

Nephron-sparing surgical intervention has been identified as a cornerstone treatment, where in accordance with the National Comprehensive Cancer Network (NCCN) guidelines, all patients with RCC stages I-III fit for the surgical procedure must undergo nephrectomy (radical or nephron-sparing) as part of the treatment plan, implying surgical intervention as the primary curative procedure in the treatment strategy. The geriatric or poor performance status patients still amenable to surgery primarily require nephron-sparing nephrectomy rather than radical nephrectomy, suggesting surgical excision as the dominant physician therapeutic approach for a better outcome in the older subset where merely age cannot be an exclusion criterion for treatment despite the higher risk involved in the former. Authors also justify the implementation of laparoscopic surgery preferably in old-age patients as the rate of complications anticipated may be low. Studies also emphasize partial nephrectomy (PN) for solitary, small RCCs less than 4 cm in size alongside positively claiming the prognosis for surgical resection of small renal tumors as satisfactory with a five-year cancer-specific survival rate of 97% and 87% for T1a and T1b, respectively.

A retrospective analysis conducted from 1988 to 2005 revealed a startling number of 59,944 patients treated for RCC with surgery, out of which 4,587 patients were aged greater than 80 years. Intriguingly, the survey clearly highlighted the burden of underlying debilitated and feeble functional status as a key factor in the progression of the disease towards mortality due to causes except for RCC. This explicitly elevates the devastating effects of age on the RCC disease course, with a fundamental necessity to establish treatment prerequisites, guidelines, and a rationale predominantly related to the elderly subset.

Ablative Therapy and Active Surveillance

Decreased life expectancy with associated co-morbidities provokes a detrimental effect and enlightens the utilization of management options such as ablative therapy or active surveillance. Ablative modality comprises cryo or radiofrequency ablation, which could be proceeded percutaneously under local anesthesia, enabling a minimally invasive treatment option for elderly frail patients with co-morbidities who cannot be intervened by the conventional surgical approach. The added advantage of the percutaneous ablative approach tends to involve an affording cost, less hospital stay duration, and a diminished rate of post-treatment complication phase in comparison to the conventional surgical modality. Thermal ablation as a successful intervention has also been acclaimed as an analogous therapeutic option to the conventional surgical approach in the aged, prioritizing its key role in considering it as a treatment guideline precisely for the elderly. Ablative modality involves ablative techniques such as cryo or radiofrequency ablation, enabling a minimally invasive treatment option for elderly frail patients with co-morbidities who cannot be intervened by the conventional surgical approach. The added advantage of the percutaneous ablative approach tends to involve an affording cost, less hospital stay duration, and a diminished rate of post-treatment complication phase in comparison to the conventional surgical modality. Thermal ablation as a successful intervention has also been acclaimed as an analogous therapeutic option to the conventional surgical approach in the aged, prioritizing its key role in considering it as a treatment guideline precisely for the elderly. Another prior scrutinization done on 84 tumors ablated demonstrated a five-year recurrence-free survival rate and a metastasis-free survival rate of 95% and 95%, respectively. These intriguing results enlighten a distinct physician approach that may be eventually considered as a rationale for the elderly subset.

Active surveillance evolves as an important observational tool, particularly in those patients with an observed slow growth rate of small renal masses. This monitoring can be highly successful where patients could be reassured that if progression occurs, a delayed operation can be proposed, with the same outcome as for immediate intervention. This can be mentioned as the least invasive yet effective therapeutic strategy particularly to be thoroughly considered in the elderly.
Metastatic RCC comprises 20–30% of patients with underlying RCC, which warrants a multidisciplinary approach. Surgical management includes cytoreductive nephrectomy in combination with metastasectomy of distant metastases. It is quite pertinent to mention the requirement of a satisfactory underlying functional status in order to acquire this treatment, especially for the older population. The positive role of this therapy, however, still remains unclear in the treatment protocol section of this literature review. The implications of Immunotherapy with interferon alfa and interleukin–2, which have been disregarded due to their potentially toxic and ineffective characteristics have been overcome by targeted therapies known to lead the treatment for metastasis [24,30].

From prolonged clinical trials, drugs, including sunitinib, Sorafenib, temsirolimus, bevacizumab, pazopanib, and everolimus have been found to be safe and effective in the elderly, frail, or in young and good performance status patients. The study, however, eventually concluded that newer targeted drugs should be offered to elderly patients with multiple co-morbidities, enhancing further treatment options in the aged [24]. Recent studies also quote an additional inclusion of improved quality of life and a cornerstone of treatment with the utilization of nivolumab with ipilimumab, specifically in poor-risk patients, which could possibly provide a major breakthrough in the quality management of the disease [37-38]. Nivolumab has also been regarded as having a pivotal role in treating pretreated cases of metastatic RCC exclusively in the aged [39].

Radiotherapy

To create a positive impact on the treatment of different tumor encounters, inoperable RCC can also be dealt with radiotherapy with surprisingly promising overall results. According to an interpretation of an analysis, 58 patients with inoperable or metastatic RCC received high-dose stereotactic radiotherapy (32Gy in four fractions, 40Gy in four fractions, or 45Gy in three fractions) where a stable disease was observed in 90% of patients with a local control rate of 90-98%. It has also been established that radiotherapy can be safely administered to elderly and frail patients and should be considered a therapeutic option whenever radical intervention is not applicable [24]. A conclusion could hence be generated where aged patients with no chance of curative resection can undoubtedly benefit from radiotherapy with positive long-term survival.

Conclusions

Therapeutic management of renal cell carcinoma in the aged subset can now be achieved and is no longer an unsuccessful task. The classic triad of symptoms, including flank pain, hematuria, and abdominal mass, usually represent an advanced stage of RCC and are not reliable for a preliminary RCC diagnosis. The frail physique of the elderly subset is linked to higher mortality due to the underlying burden of co-morbidities. Regular and treatment-compliant patient follow-ups for an early tumor diagnosis and, eventually, better overall survival appears to be a primary key factor. Despite the cynical facts related to management and statistics, advanced age should not be contemplated as a sole barrier to surgery. Percutaneous ablation and immunotherapy with nivolumab have been established as an efficacious therapeutic strategy in the elderly subset for RCC. Nephron-sparing nephrectomy should be prioritized over radical nephrectomy, particularly in the aged population diagnosed with localized tumor configuration. Elderly and frail patients must be included in clinical trials in order to determine safe and effective treatment strategies and protocols for the future.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Quiry A, Daste A, Harbaoui A, Duc S, Bernhard JC, Gross-Goupil M, Ravaud A: Optimal management of renal cell carcinoma in the elderly: a review. Clin Interv Aging. 2015, 8:433-42. 10.2147/CIA.S50765
2. Fujita T, Hisayama T, Ishii D, Matsumoto K, Yoshida K, Iwamura M: Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma. Mol Clin Oncol. 2018, 9:594-8. 10.5892/mco.2018.1684
3. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr: Rising incidence of renal cell cancer in the United States . JAMA. 1999, 281:1628-31. 10.1001/jama.281.17.1628
4. Cairns P: Renal cell carcinoma. Cancer Biomark. 2010, 9:461-73. 10.3233/CBM-2011-0176
5. Berdjin N, Hakenberg OW, Novotry V, Frohner M, Wirth MP: Treating renal cell cancer in the elderly . BJU Int. 2006, 97:705-5. 10.1111/j.1464-410X.2006.06015.x
6. Capitanio U, Bensalah K, Rex A, et al.: Epidemiology of renal cell carcinoma. Eur Urol. 2019, 75:74-84.
Renal cell carcinoma (RCC) in the elderly: a review of the role of obesity in RCC. Endcancer. 2021, 28:8207-16. 10.1530/ERC-20-0457

Economic burden of renal cell carcinoma-part I: an updated review. Pharmacoconomics. 2019, 37:301-31. 10.1007/s40273-018-0746-y

Therapeutic challenges in renal cell carcinoma. J Clin Exp Urol. 2015, 5:37-48.

Economic burden of renal cell carcinoma-part II: an updated review. PharmacoEconomics. 2019, 37:301-31. 10.1007/s40273-018-0746-y

Obesity in RCC. J BUON. 2019, 24:2147-54.

Pericutaneous ablation techniques for renal cell carcinoma: current status and future trends. Int J Hyperthermia. 2019, 36:21-30. 10.1080/02656673.2019.1647352

Comparative effectiveness of thermal ablation, surgical resection, and active surveillance for T1a renal cell carcinoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked population study. Radiology. 2018, 288:81-90. 10.1148/radiol.2018171407

Active surveillance in small renal masses in the elderly: a literature review. Eur Urol Focus. 2017, 5:340-51. 10.1016/j.euf.2017.11.005

Patient-reported outcomes in patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus nivolumab. Lancet Oncol. 2019, 20:297-310. 10.1016/S1470-2045(18)30778-2

Ipilimumab and nivolumab as first-line treatment of patients with metastatic renal cell carcinoma. J BUON. 2019, 24:2147-54.

Clinical presentation of renal cell carcinoma. J Ayub Med Coll Abbottabad. 2015, 37:326-8.

Renal cell carcinoma: management in the elderly. Curr Geriatr Rep. 2014, 3:19-25.

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma. J Urol. 2015, 193:30125-6.